Interestingly, a series of works from Fu and his colleagues showed that therapeutic roles of commonly used antibodies in oncology (against Her2, EGFR and CD20 for example) are dependent on T cells [82–84], providing a rationale for combining these antibodies with ICIs for cancer immunotherapy. The gene discussed is ERBB2; the disease is cancer.